Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Expression of Programmed Death Ligand-1 (PD-L1) on Advanced Osteosarcoma Tissue and Its Influence on Prognosis

NCT03582527 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03582527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03582527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Expression of Programmed Death Ligand-1 (PD-L1) on Advanced Osteosarcoma Tissue and Its Influence on Prognosis
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2018
Completion date
February 15, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

progression, survival